Kala Pharmaceuticals (NSDQ:KALA) this month expanded its team of C-suite executives, naming Todd Bazemore as chief operating officer. Bazemore has spent more than 20 years in the biopharmaceutical industry, most recently working as EVP and COO for Santhera Pharmaceuticals. He has also spent time at Dyax Corp., Sunovion Pharmaceuticals, and Muro Pharmaceuticals. “We welcome Todd to […]
Gamida Cell launches severe aplastic anemia trial
Gamida Cell said today that the first patient has been transplanted in a study of its CordIn product for patients with severe aplastic anemia or hypoplastic myelodysplastic syndrome. The product is designed for patients with rare genetic diseases who have no fully-matched donors for a bone marrow transplantation. Gamida Cell said it is also evaluating its […]
Gamida Cell lands $40m for late-stage NiCord trial
Gamida Cell said today that it raised $40 million to support the ongoing Phase III trial of its NiCord cell graft and expand its in-house manufacturing capacity. The private financing was led by new investor Shavit Capital. VMS Investment Group and Israel Biotech Fund joined existing investor Novartis in the round, as well as Clal Biotechnology […]
Study: Gamida Cell’s NiCord cell graft yields fewer infections, shorter hospital stays
Gamida Cell said today that its NiCord cell graft produces fewer infections, shorter hospital stays and shorter time to engraftment compared to standard umbilical cord blood transplantation. The company’s work was published in Biology of Blood and Marrow Transplantation. Get the full story at our sister site, Drug Delivery Business News.
Gamida Cell wins additional EMA orphan drug designation for NiCord
Gamida Cell said today that the European Medicines Agency granted its NiCord cell graft an additional orphan drug designation as a treatment for hematopoietic stem cell transplantation, or bone marrow transplantation. The treatment is a graft derived from umbilical cord blood which has been expanded and enriched with stem and progenitor cells, according to the […]
Gamida Cell touts first patient treated in Phase III NiCord trial
Gamida Cell said today that the 1st patient has been treated in the Phase III registration trial of its NiCord cell graft for patients with blood cancer. The treatment is a graft derived from umbilical cord blood which has been expanded and enriched with stem and progenitor cells, according to the company. The Jerusalem-based company’s cell […]
Gamida Cell wins FDA breakthrough therapy designation for NiCord cell graft
Gamida Cell said today that it won breakthrough therapy designation from the FDA for its lead product candidate, NiCord. The Jerusalem-based company’s expanded cell graft is designed to be an alternative to bone marrow transplantation for patients with high-risk hematological cancers. Gamida Cell said it plans to launch an international Phase III registration study of the […]
MassDevice Network
@MassDevice
LinkedIn
YouTube